Citi upgraded Teva Pharma (NYSE: TEVA) from Neutral to Buy with a price target of $24.00 (from $16.00).Analyst Liav Abraham ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE